Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$2.11 - $3.25 $20,899 - $32,191
9,905 Added 104.27%
19,404 $60,000
Q3 2022

Nov 14, 2022

BUY
$1.32 - $3.14 $12,538 - $29,826
9,499 New
9,499 $25,000
Q3 2022

Nov 14, 2022

BUY
$1.32 - $3.14 $12,538 - $29,826
9,499 New
9,499 $25,000
Q1 2021

May 11, 2021

SELL
$3.62 - $6.34 $22,914 - $40,132
-6,330 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$3.82 - $5.32 $24,180 - $33,675
6,330 New
6,330 $32,000
Q3 2019

Nov 07, 2019

SELL
$2.47 - $3.51 $347,776 - $494,207
-140,800 Closed
0 $0
Q2 2019

Aug 08, 2019

BUY
$3.06 - $51.61 $430,848 - $7.27 Million
140,800 New
140,800 $445,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $99M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.